文献速递支持与姑息治疗

bulky I/II期经典型霍奇金淋巴瘤的PET适应治疗:CALGB 50801(Alliance)

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
PubMed 文献 · J Clin Oncol · 2022-10-21

研究纳入94例可评估的bulky I/II期经典型霍奇金淋巴瘤患者,接受2周期ABVD后行中期PET(PET2),PET2阴性者继续4周期ABVD,PET2阳性者接受4周期 escalated BEACOPP后行30.6 Gy累及野放疗。全组3年无进展生存率为92.3%,达到主要终点。

要点

  • PET2阴性患者3年PFS为93.1%,PET2阳性患者为89.7%。
  • PET2阳性与阴性患者PFS的估计风险比为1.03(85%上限2.38),显著低于无效假设4.1(单侧P=0.04)。
  • 主要毒性为中性粒细胞减少,9%患者发生发热性中性粒细胞减少,1例发生脓毒症。

核心结论

  • bulky I/II期经典型霍奇金淋巴瘤的PET适应治疗研究达到主要目标,全组3年PFS率为92.3%,大多数患者得以免除放疗和强化化疗。

研究设计与样本

  • 研究纳入bulky(肿块>10 cm或胸部X线最大胸内径的1/3)I/II期经典型霍奇金淋巴瘤患者,接受2周期ABVD后行中期FDG PET(PET2)。
  • PET2阴性(5分量表1-3分)者接受4周期额外ABVD;PET2阳性者接受4周期escalated BEACOPP后行30.6 Gy累及野放疗。

主要发现

  • 94例可评估患者中,53%为女性,中位年龄30岁(范围18-58岁);85例(90%)为II期,其中48例(51%)为IIB/IIBE期。
  • 78例(78%)为PET2阴性,21例(22%)为PET2阳性。
  • 主要毒性为中性粒细胞减少,9%患者发生发热性中性粒细胞减少,1例发生脓毒症。
  • PET2阴性患者3年PFS为93.1%,PET2阳性患者为89.7%;3年总生存率分别为98.6%和94.4%。
  • PET2阳性与PET2阴性患者PFS的估计风险比为1.03(85%上限2.38),显著低于无效假设4.1(单侧P=0.04)。

关键数值与推荐

  • PET2阴性定义为5分量表1-3分。
  • PET2阳性患者接受4周期escalated BEACOPP后行30.6 Gy累及野放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation. Late effects associated with radiotherapy include increased risk of second cancer and cardiovascular disease. We tested a positron emission tomography (PET)-adapted approach in patients with bulky, early-stage cHL, omitting radiotherapy in patients with interim PET-negative (PET-) disease and intensifying treatment in patients with PET-positive (PET+) disease. METHODS: Eligible patients with bulky disease (mass > 10 cm or 1/3 the maximum intrathoracic diameter on chest x-ray) received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim fluorodeoxyglucose PET (PET2). Patients with PET2-, defined as 1-3 on the 5-point scale, received four additional cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Patients with PET2+ received four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone followed by 30.6 Gy involved-field radiation. RESULTS: Of 94 evaluable patients, 53% were female with median age 30 years (range, 18-58 years). Eight-five (90%) had stage II disease, including 48 (51%) with stage IIB/IIBE. Seventy-eight (78%) were PET2- and 21 (22%) were PET2+. The predominant toxicity was neutropenia, with 9% of patients developing febrile neutropenia and one developing sepsis. The primary end point of 3-year progression-free survival (PFS) was 93.1% in PET2- and 89.7% in PET2+ patients. Three-year overall survival was 98.6% and 94.4%, respectively. The estimated hazard ratio comparing PFS of patients with PET2+ and patients with PET2- was 1.03 (85% upper bound 2.38) and was significantly less than the null hypothesis of 4.1 (one-sided P = .04). CONCLUSION: Our study of PET-adapted therapy in bulky stage I/II cHL met its primary goal and was associated with an excellent 3-year PFS rate of 92.3% in all patients, with the majority being spared radiotherapy and exposure to intensified chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. LaCasce AS, Dockter T, Ruppert AS, et al. Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). J Clin Oncol. 2022. PMID: 36269899. doi:10.1200/JCO.22.00947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。